Start here if you're new
what it is
Aprea is trying to turn a few early cancer drug programs into an actual business.
how it gets paid
Last year Aprea Therapeutics made $1M in revenue. Legacy and other revenue was the main engine at $2M, or 100% of sales.
what just happened
The key takeaway is simple: quarterly losses narrowed to -$0.49 in Q4 2024 from -$0.92 a year earlier.
At a glance
C+ balance sheet — struggling to keep the lights on
40/100 earnings predictability — expect surprises
-$2.35 fy2024 eps est
$2M fy2024 rev est
1.4 beta
xvary composite: 29/100 — weak
What they do
Aprea is trying to turn a few early cancer drug programs into an actual business.
The edge is focus. Aprea has 8 employees and is aimed at DNA damage response drugs, which means your bet is concentrated, not diversified. Clinical-stage → human testing has started → so what: ATRN-119 gives the company one real shot to prove the science.
How they make money
$1M
annual revenue
Legacy and other revenue
$2M
ATRN-119 program
$0M
WEE1 inhibitor program
$0M
ATRN-354 program
$0M
The products that matter
clinical-stage oncology drug candidate
APR-1051
Phase 1/2 trial · one clinical asset
this is the entire equity story. a $5M company with $14.6M in cash is being judged almost entirely on whether this Phase 1/2 program produces data investors can believe.
binary catalyst
Key numbers
$2M
2024 revenue est
Revenue estimate → expected sales this year → so what: this is still a science project, not a scaled business.
$2.35
2024 EPS est
EPS → profit per share → so what: Aprea is still expected to lose about $2.35 for every share outstanding in 2024.
$3.1M
private placement
Private placement → selling stock to raise cash → so what: the financing equals about 62% of a $5 million market cap.
8
employees
Headcount → people on payroll → so what: this is a very small operation trying to push multiple oncology programs forward.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for APRE right now.
source: institutional data · return history unavailable
What just happened
beat estimates
The key takeaway is simple: quarterly losses narrowed to -$0.49 in Q4 2024 from -$0.92 a year earlier.
There is no real revenue story yet. The only clear trend in the quarterly data is that losses got smaller through 2024, with full-year EPS improving to -$2.35 from -$3.95 in 2023.
$0.49
q4 2024 eps
$0.92
q4 2023 eps
$2.35
fy2024 eps
the number that mattered
The number that mattered was -$2.35, because a smaller annual loss is the closest thing Aprea has to operating progress right now.
source: quarterly EPS history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is APR-1051 failing to produce financeable data before the cash runway ends. for APRE, the science and the balance sheet are tied together.
med
going-concern risk is not theoretical
The company has already disclosed going-concern risk, and it reports $14.6M in cash with runway only through Q1 2027. That leaves little room for a long delay or a failed readout.
If cash burn accelerates or financing closes on poor terms, your ownership gets diluted before the pipeline is proven.
med
one asset means one point of failure
APR-1051 is the only clinical-stage asset highlighted here. There is no diversified revenue base and no second approved product to absorb a miss.
If APR-1051 disappoints, the market cap can stop looking absurdly cheap and start looking directionally correct.
med
Phase 1/2 is early, and early usually fails
Roughly 90% of drugs at this stage never reach approval. That statistic does not decide APRE's fate on its own, but it tells you the default outcome for programs this early.
The upside can be multiple times the current stock price. The more common outcome in this asset class is capital loss.
A forced capital raise before convincing data would pressure the stock directly, because the company is worth only about $5M against $14.6M in cash. That gap looks attractive until you remember why the market put it there.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
APR-1051 clinical data
Phase 1/2 updates expected in Q1 2026. This is the event that can justify the cash discount or confirm it.
balance sheet
cash balance after Q4
Watch whether the reported cash figure still supports management's runway claim through Q1 2027.
financing risk
any equity raise before strong data
A financing done before a credible readout would tell you the company values survival over negotiating leverage. Fair enough. Bad for existing holders.
pipeline pace
trial timeline discipline
At this size, delays matter almost as much as weak data. The trend you care about is schedule integrity, not chart momentum.
Analyst rankings
short-term outlook
speculative
traditional ranking systems break a little here. in human-speak, analysts are not grading steady execution — they are grading a single upcoming data event.
risk profile
extreme risk
risk rank 5 and price stability 5/100 tell you this stock is riskier than about 95% of the market. that is not color. that is the product.
earnings predictability
40 / 100
predictability is low, but the deeper point is simpler: this is not an earnings story. it is a funding-and-data story.
source: institutional data
Institutional activity
institutional ownership data for APRE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive